Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) announced that oral nalmefene hydrochloride, an opiate antagonist under development by the company, demonstrated positive results in a pilot Phase 2 clinical trial for smoking cessation.
For further information please refer to www.somaxon.com.
BioTie has lisenced the North-American rights of nalmefene to Somaxon Pharmaceuticals.
Turku, 27 July, 2006
Biotie Therapies Corp.
Timo Veromaa President and CEO
For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp. tel. +358 2 274 8901, e-mail: email@example.com www.biotie.com
DISTRIBUTED TO Helsinki Exchanges The main media